ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.

ChemoSNiP analyses a blood sample to identify single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments with chemicals, drugs and other agents.

ChemoSNiP provides clinicians with a powerful insight into which drugs are most effective at treating cancer. The results provide a personalised analysis that can be used to provide the most effective combination of drugs and treatments available.